Literature DB >> 16337786

Management and prognosis of esophageal cancers: has progress been made?

A M Bouvier1, C Binquet, A Gagnaire, J L Jouve, J Faivre, L Bedenne.   

Abstract

The aim of this study was to investigate time trends in treatment and prognosis of esophageal cancer in a well-defined French population. Data was obtained from the Burgundy Cancer Registry (France) and three time periods were defined: 1976-90, 1991-96 and 1997-2002. A logistic regression was used to identify factors associated with an R0 resection. A multivariate survival analysis was performed using a Cox model. From 1976 to 2002, 2267 patients were included. The R0 resection rate slightly increased from 20.9% to 25.8% (P=0.019) then remained stable. Operative mortality decreased from 11.7% to 6.7% (NS). Age and subsite significantly influenced the rate of resection for cure whereas period had no effect. Chemotherapy alone was seldom used and radiotherapy alone dramatically dropped over time. Chemoradiation used as adjuvant treatment increased from 16.3% (1976-90) to 30.6% (1997-02) (P<0.001) and as sole treatment from 16.0% to 48.5% (P<0.001). The 3-year survival rates were respectively 10.1% and 9.7% (NS). Age and stage at diagnosis influenced the prognosis of esophageal cancer whereas time period and histology had no influence. This study claims that esophageal cancer remains a serious cancer problem and no improvement has been seen in the study population in France in its management over time.

Entities:  

Mesh:

Year:  2005        PMID: 16337786     DOI: 10.1016/j.ejca.2005.08.038

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  11 in total

1.  Are we making progress in diagnosing and preventing gastrointestinal cancers?

Authors:  Jelle Haringsma; Nicoline C M van Heel; Ernst J Kuipers
Journal:  Therap Adv Gastroenterol       Date:  2010-07       Impact factor: 4.409

2.  Characterization of a novel tumorigenic esophageal adenocarcinoma cell line: OANC1.

Authors:  Nicholas J Clemons; Hongdo Do; Christina Fennell; Siddhartha Deb; Andrew Fellowes; Alexander Dobrovic; Wayne A Phillips
Journal:  Dig Dis Sci       Date:  2014-01       Impact factor: 3.199

3.  Survival trends in patients with gastric and esophageal adenocarcinomas: a population-based study.

Authors:  Sarah J Crane; G Richard Locke; William S Harmsen; Alan R Zinsmeister; Yvonne Romero; Nicholas J Talley
Journal:  Mayo Clin Proc       Date:  2008-10       Impact factor: 7.616

4.  Clinical characteristics and outcome of patients with stage III esophageal carcinoma: a single-center experience from Turkey.

Authors:  Vahide I Ugur; Sakire P Kara; Bulent Kucukplakci; Taciser Demirkasimoglu; Cem Misirlioglu; Aytul Ozgen; Yesim Elgin; Ergun Sanri; Kadri Altundag; Nadi Ozdamar
Journal:  Med Oncol       Date:  2007-07-20       Impact factor: 3.064

5.  The characteristics of oesophageal squamous cell carcinoma: an analysis of 1317 cases in southeastern China.

Authors:  Yuan-Xi Jiang; Dong-Wei Zhang; Ying Chen; Hui-Hui Sun; Shu-Chang Xu; Heng-Jun Gao
Journal:  Contemp Oncol (Pozn)       Date:  2015-05-13

6.  Nomogram to predict treatment outcome of fluoropyrimidine/platinum-based chemotherapy in metastatic esophageal squamous cell carcinoma.

Authors:  Hyun Ae Jung; Antoine Adenis; Jeeyun Lee; Se Hoon Park; Chi Hoon Maeng; Silvia Park; Hee Kyung Ahn; Young Mog Shim; Nicolas Penel; Young-Hyuck Im
Journal:  Cancer Res Treat       Date:  2013-12-31       Impact factor: 4.679

Review 7.  Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction.

Authors:  Nicholas J Clemons; Wayne A Phillips; Reginald V Lord
Journal:  Cancer Biol Ther       Date:  2013-06-17       Impact factor: 4.742

8.  Antireflux versus conventional self-expanding metallic Stents (SEMS) for distal esophageal cancer: results of a multicenter randomized trial.

Authors:  E Coron; G David; S Lecleire; J Jacques; A Le Sidaner; T Barrioz; D Coumaros; C Volteau; B Vedrenne; P Bichard; C Boustière; Y Touchefeu; J Brégeon; F Prat; M Le Rhun
Journal:  Endosc Int Open       Date:  2016-06

9.  Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer.

Authors:  T Conroy; F Viret; E François; J F Seitz; V Boige; M Ducreux; M Ychou; J P Metges; M Giovannini; Y Yataghene; D Peiffert
Journal:  Br J Cancer       Date:  2008-10-07       Impact factor: 7.640

10.  Survival outcomes for patients with four treatments in stages I-III esophageal squamous cell carcinoma: a SEER analysis.

Authors:  Jingyang Wu; Jiansheng Yang; Xianbin Lin; Liang'an Lin; Wentan Jiang; Chengke Xie
Journal:  Transl Cancer Res       Date:  2021-05       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.